Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Phase 2b Study of Selinexor in Combination with Pomalidomide in Patients with Pomalidomide-Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7070.

https://doi.org/10.1182/blood-2024-208473

Published: 2024

Journal Articles

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

Blood (2023) 142 (Supplement 1): 2022.

https://doi.org/10.1182/blood-2023-189907

Published: 2023

Journal Articles

Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma

Rena Feinman, Ariel Aptekmann, Iriana Colorado, Samuel Roy, Katelyn Quino, Noreen Ahmed, Adolfo Aleman, Rashmi Unawane, Joshua Zenreich, Alana Barofsky, Kashish Bhatt, Michele L. Donato, Noa Biran, David S. Siegel

Blood (2023) 142 (Supplement 1): 3294.

https://doi.org/10.1182/blood-2023-190108

Published: 2023

Journal Articles

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

Blood (2023) 142 (Supplement 1): 6714.

https://doi.org/10.1182/blood-2023-187011

Published: 2023

Journal Articles

Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 4843–4844.

https://doi.org/10.1182/blood-2022-168934

Published: 2022

Journal Articles

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Rena Feinman, PhD, Tracy Andrews, MSc, Iriana Colorado, MSc, Joshua Zenreich, Suzanne Kosky, BS, Themba Nyirenda, PhD, Noa Biran, MD, David S Siegel, MD PhD, David H. Vesole, MD PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Pashna N. Munshi, MD, Michael B Atkins, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Andre Goy, MD, Robert Korngold, PhD, Alan P Skarbnik, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 3443.

https://doi.org/10.1182/blood-2018-99-117669

Published: 2018

Journal Articles

Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma

Andre Goy, MD, Tatyana A Feldman, MD, Lori A. Leslie, MD, Rima Panchal Panchal, Intern, Themba Nyirenda, PhD, Alan P Skarbnik, MD, Kara Yannotti, BSN, Joshua Zenreich, Colleen M Bejot, APN, Susan Stives, APN, Kar Fai Chow, MD, Pritish K. Bhattacharyya, MD, Xiao Yang, Ernest Richards, PhD

Blood (2017) 130 (Supplement 1): 2785.

https://doi.org/10.1182/blood.V130.Suppl_1.2785.2785

Published: 2017

Journal Articles

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Noa Biran, MD, Tracy Andrews, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Joshua Zenreich, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Robert Korngold, PhD, David Siegel, MD PhD

Blood (2017) 130 (Supplement 1): 1831.

https://doi.org/10.1182/blood.V130.Suppl_1.1831.1831

Published: 2017

Journal Articles

Preliminary Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies - Cpit-001 Trial

Blood (2017) 130 (Supplement 1): 340.

https://doi.org/10.1182/blood.V130.Suppl_1.340.340

Published: 2017

Journal Articles

Venous Assessment Prior to Mobilization Significantly Reduced Use of Apheresis Central Venous Catheters

Michele Boonstra, MSN APN, Melissa Baker, APN, Tracy Andrews, MA, Maria Cortes, APN, Ann Marie Maguire, BSN, Sarina Torres, BSN, Joshua Zenreich, BS, CCRP, Lina Starovoitova, BS, CCRP, Scott D. Rowley, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Andre Goy, MD, David H. Vesole, MD PhD, Michele L. Donato, MD

Blood (2016) 128 (22): 5735.

https://doi.org/10.1182/blood.V128.22.5735.5735

Published: 2016

Journal Articles

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR 2 Regimen

Anthony R. Mato, MD MSCE, Kenneth A. Foon, MD, Tatyana Feldman, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Kar Fai Chow, MD, Marisa Valentinetti, BS, Mary Morin, BS, Kelly Azzollini, BS, Gabriella Magarelli, MS, Pritish K. Bhattacharyya, MD, Joshua Zenreich, BS, Christina Howlett, PharmD, BCOP, Lauren-Nicole Pascual, BS, Kara Yanotti, BSN, Sabrina Kdiry, BSN, David Porter, MD, Andre Goy, MD

Blood (2014) 124 (21): 4678.

https://doi.org/10.1182/blood.V124.21.4678.4678

Published: 2014

NARROW

A Phase 2b Study of Selinexor in Combination with Pomalidomide in Patients with Pomalidomide-Refractory Multiple Myeloma

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Preliminary Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies - Cpit-001 Trial

Venous Assessment Prior to Mobilization Significantly Reduced Use of Apheresis Central Venous Catheters

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR 2 Regimen

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only